atai Life Sciences Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health Approaches for Positive Social Change
October 19 2021 - 7:00AM
atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage
biopharmaceutical company, today announced the launch of its new
philanthropic program, atai Impact, in line with atai Life
Sciences’ vision, to heal mental health disorders so that everyone,
everywhere can live a more fulfilled life.
atai Impact has been developed to harness the power of
innovative mental health approaches for positive social change,
committed to advancing education, expanding access and supporting
the wider ecosystem.
Its establishment is based on atai Life Sciences’ position that,
while a for-profit model is the swiftest and most robust means of
unlocking new modalities for patients in need, this model alone
cannot address all aspects of the escalating global mental
crisis.
Therefore, atai Life Sciences believes having harmonization
among commercial and non-profit entities is the ideal way forward.
The initial focus of atai Impact will be on the psychedelic sector,
given its emerging potential in tackling the growing mental health
crisis.
Supporting and collaborating with nonprofits and institutions
that share its vision of healing mental health disorders, atai
Impact will operate across three central pillars:
- Education: to help destigmatize mental health, promote better
understanding of the potential of psychedelics in mental health
care, and foster the next generation of neuro-innovators.
- Access: to support equal access to innovative and effective
mental health support, for everyone, everywhere, regardless of
geography or demographics.
- Ecosystem: to contribute to the sustainability of diverse
stakeholder communities and environments, including indigenous
resources.
“The launch of atai Impact is a very proud moment for everyone
at atai Life Sciences and for me, personally. While we believe a
for-profit model is the best way to get new treatments to patients
in need, not all aspects of the global mental health crisis can be
effectively addressed by this model alone,” said Florian Brand,
Chief Executive Officer and Co-founder of atai Life Sciences.
“I’ve been moved by the huge volume of support, internally and
externally, that we have had in bringing atai Impact to life and by
the commitment of so many of our staff, founders and investors
who’ve already joined me in contributing a portion of their own
company equity to this important program. We are in active
discussions with multiple stakeholders towards meaningful
initiatives that we believe can help make a real difference to the
future of psychedelic medicine and mental health care
worldwide.”
The atai Impact program will be initially funded by 1% of the
gross proceeds from atai Life Sciences’ June 2021 Initial Public
Offering (NASDAQ) and founders’ contributions. In
addition, atai Life Sciences has created a Volunteer Paid
Time Off Policy, equal to 1% of employees’ time, and is working
with the Equity for Impact initiative to encourage employees and
investors to donate a portion of their equity to charitable
endeavors.
About atai Life Sciences
atai is a clinical-stage biopharmaceutical company aiming to
transform the treatment of mental health disorders. atai was
founded in 2018 as a response to the significant unmet need and
lack of innovation in the mental health treatment landscape. atai
is dedicated to acquiring, incubating and efficiently developing
innovative therapeutics to treat depression, anxiety, addiction,
and other mental health disorders. atai's business model combines
funding, technology, scientific and regulatory expertise with a
focus on psychedelic therapy and other drugs with differentiated
safety profiles and therapeutic potential. By pooling resources and
best practices, atai aims to responsibly accelerate the development
of new medicines across its companies, seeking to effectively treat
and ultimately heal mental health disorders. atai's mission is to
bridge the gap between what the mental healthcare system currently
provides and what patients need. atai has offices in New York,
London, and Berlin. For more information, please visit
www.atai.life.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Any express or implied statements contained in this press
release (including without limitation, the atai Impact program and
any other future philanthropic endeavors by atai) that are not
statements of historical fact may be deemed to be forward-looking
statements. Forward-looking statements are neither promises nor
guarantees, but involve known and unknown risks and uncertainties
that could cause actual results to differ materially from those
projected, including, without limitation, the important factors
discussed under the caption “Risk Factors” in atai's prospectus
pursuant to Rule 424(b) filed with the U.S. Securities and Exchange
Commission (“SEC”) on June 21, 2021, as such factors may be updated
from time to time in atai's other filings with the SEC. atai
disclaims any obligation or undertaking to update or revise any
forward-looking statements contained in this press release, other
than to the extent required by applicable law.
Contact Information
For atai:
Media Contact:Camilla DormerVP, Communications, atai Life
SciencesEmail: camilla@atai.life
Investor Contact:Chad MesserVP, Investor Relations, atai Life
SciencesEmail: chad@atai.life
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Jun 2024 to Jul 2024
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Jul 2023 to Jul 2024